Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Intensive combined therapy for previously untreated aggressive myeloma.

Attal M, Huguet F, Schlaifer D, Payen C, Laroche M, Fournie B, Mazieres B, Pris J, Laurent G.

Blood. 1992 Mar 1;79(5):1130-6.

2.

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.

Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Fibbe WE, Wittebol S, Schouten HC, van Marwijk Kooy M, Biesma DH, Baars JW, Slater R, Steijaert MM, Buijt I, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Study Group.

Blood. 2003 Mar 15;101(6):2144-51. Epub 2002 Nov 27.

3.

Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors.

Jagannath S, Barlogie B, Dicke K, Alexanian R, Zagars G, Cheson B, Lemaistre FC, Smallwood L, Pruitt K, Dixon DO.

Blood. 1990 Nov 1;76(9):1860-6.

4.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
5.

Total therapy with tandem transplants for newly diagnosed multiple myeloma.

Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J.

Blood. 1999 Jan 1;93(1):55-65.

6.

Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.

Lokhorst HM, Sonneveld P, Cornelissen JJ, Joosten P, van Marwijk Kooy M, Meinema J, Nieuwenhuis HK, van Oers MH, Richel DJ, Segeren CN, Veth G, Verdonck LF, Wijermans PW.

Bone Marrow Transplant. 1999 Feb;23(4):317-22.

7.

The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma.

Davies FE, Forsyth PD, Rawstron AC, Owen RG, Pratt G, Evans PA, Richards SJ, Drayson M, Smith GM, Selby PJ, Child JA, Morgan GJ.

Br J Haematol. 2001 Mar;112(3):814-9.

PMID:
11260088
8.

Prolonged survival after intensive therapy and purged ABMT in patients with multiple myeloma.

Reece DE, Brockington DA, Phillips GL, Barnett MJ, Klingemann HG, Nantel SH, Sutherland HJ, Shepherd JD.

Bone Marrow Transplant. 2000 Sep;26(6):621-6.

9.

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R.

N Engl J Med. 1996 Jul 11;335(2):91-7.

10.

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC.

J Clin Oncol. 2006 Feb 20;24(6):929-36. Epub 2006 Jan 23. Erratum in: J Clin Oncol. 2006 Jun 10;24(17):2687. Moore, Dennis F Jr [added].

PMID:
16432076
12.

High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.

Kumar L, Raju GM, Ganessan K, Shawgi S, Menon H, Wadhwa J, Sharma A, Singh R, Kochupillai V.

Natl Med J India. 2003 Jan-Feb;16(1):16-21.

PMID:
12715951
13.

[Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].

Marisavljević D, Bosković D, Radosević N, Elezović I, Tomin D, Gotić M, Antunović P.

Srp Arh Celok Lek. 1996 Nov-Dec;124(11-12):292-6. Serbian.

PMID:
9132962
14.

[Progress in the treatment of multiple myeloma].

Wada M, Mizoguchi H.

Gan To Kagaku Ryoho. 1997 Jul;24(9):1079-88. Review. Japanese.

PMID:
9239160
15.

Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma.

Bastion Y, Brice P, Haioun C, Sonet A, Salles G, Marolleau JP, Espinouse D, Reyes F, Gisselbrecht C, Coiffier B.

Blood. 1995 Oct 15;86(8):3257-62.

16.

Induction therapy consisting of alternating cycles of ranimustine, vincristine, melphalan, dexamethasone and interferon alpha (ROAD-IN) and a randomized comparison of interferon alpha maintenance in multiple myeloma: a co-operative study in Japan.

Wada M, Mizoguchi H, Kuriya SI, Taguchi H, Kawamura T, Maekawa I, Shimazaki C, Sato Y, Niho Y, Miyazaki T, Shibata A, Kitani T, Hamajima N, Ohno R.

Br J Haematol. 2000 Jun;109(4):805-14.

PMID:
10929034
17.

Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group.

Zervas K, Pouli A, Perifanis V, Papanastasiou K, Chatziyianni M, Mitsouli C, Maniatis A.

Eur J Haematol. 1996 Aug;57(2):142-8.

PMID:
8856091
18.

Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study.

Tribalto M, Amadori S, Cudillo L, Caravita T, Del Poeta G, Meloni G, Avvisati G, Petrucci MT, Pulsoni A, Leone G, Sica S, Martelli M, Tabilio A, Fioritoni G, Majolino I, Mandelli F.

Haematologica. 2000 Jan;85(1):52-8.

19.

Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.

Powles R, Raje N, Milan S, Millar B, Shepherd V, Mehta J, Singhal S, Kulkarni S, Viner C, Gore M, Cunningham D, Treleaven J.

Bone Marrow Transplant. 1997 Sep;20(6):435-43.

20.

Maintenance treatment with recombinant alpha interferon after autologous bone marrow transplantation for aggressive myeloma in first remission after conventional induction chemotherapy.

Attal M, Huguet F, Schlaifer D, Payen C, Lassoued S, Laroche M, Rossi JF, Fournie B, Mazieres B, Pris J, et al.

Bone Marrow Transplant. 1991 Aug;8(2):125-8.

PMID:
1933053

Supplemental Content

Support Center